Gerresheimer's June Deadline: Auditors, Lawsuits, and a Fight for Survival

Gerresheimer faces a perfect storm: delayed audit, legal probes, and loan defaults. The German packaging firm is selling assets and negotiating with creditors as its share price plunges.

The clock is ticking for Gerresheimer. The German packaging specialist faces a critical convergence of legal, financial, and operational pressures, with a certified annual report for 2025 now delayed until June 2026 serving as the pivotal deadline. The company's struggle to regain stability is unfolding on multiple fronts simultaneously.

Legal scrutiny has expanded beyond the company itself. Germany’s audit oversight body, APAS, has initiated professional misconduct proceedings against auditor KPMG. The allegation is severe: KPMG issued an unqualified audit opinion on the 2024 accounts despite the presence of systematic revenue recognition errors. These involved so-called "bill-and-hold" agreements, where goods were invoiced but delivered later—a clear breach of IFRS rules. The flawed bookings amount to EUR 35 million in revenue and EUR 24 million in adjusted EBITDA. In a striking detail, KPMG had only just replaced predecessor Deloitte in 2024. A separate firm, Grant Thornton, is now conducting a special audit of the books for both 2024 and 2025.

Parallel to this, shareholder association DSW is preparing the ground for damages claims. It is examining potential lawsuits against former CEO Dietmar Siemssen and ex-CFO Bernd Metzner, with a focus on valuation questions surrounding business assets worth around EUR 676 million and technology values in the Advanced Technologies division. DSW has indicated that a litigation financier could become involved if claims are sufficiently clear.

These escalating legal threats compound a severe liquidity crunch. By violating contractual reporting obligations, Gerresheimer is in technical default on its loans. Management is currently negotiating with creditors to secure extensions. To shore up its balance sheet, the company has put its US drug packaging unit, Centor, up for sale via Morgan Stanley. The division was last valued on the books at EUR 292 million. Accompanying this, Gerresheimer will close its Chicago Heights plant by the end of 2026.

The financial reporting paralysis has frozen the entire corporate calendar. The Q1 2026 report and the annual general meeting have been postponed indefinitely. For the 2025 fiscal year, the company anticipates non-cash impairment charges of EUR 220 to 240 million, primarily from write-downs on technology projects at Sensile Medical AG and US assets.

Despite the profound uncertainty, some institutional investors are seeing opportunity in the steep decline. CastleKnight and Deka Investment have recently reported new stakes, buying into a share price that has plummeted approximately 67% over the past twelve months. Their moves position them against still-active short sellers.

Any potential rescue via acquisition remains structurally blocked for now. While US packaging group Silgan Holdings reportedly expressed takeover interest in March, with Reuters suggesting a potential offer of EUR 41 per share, talks are in a very early stage. A credible deal cannot proceed without audited financial statements.

All forward guidance now carries a heavy caveat. Gerresheimer's revenue forecast of EUR 2.3 to 2.4 billion for 2026 is explicitly conditional on successful credit negotiations and the outcome of ongoing BaFin investigations. The delayed certified annual report, now expected in June 2026, has become the company's most urgent milestone. Management must use that moment to present clean numbers while simultaneously proving its financing is secure and its sales targets attainable. The subsequent half-year report is scheduled for July 14, 2026, offering the next glimpse into whether the company can navigate its way out of crisis.